

# Tanox

[View the current Tanox Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/10015-Tanox.html>)

## Contact Details:

**10555 Stella Link**

**Houston**

**TX**

**77025-5631**

**United States of America**

Tel: 713-578-4000

Fax: 713-578-5000

Email: [info@tanox.com](mailto:info@tanox.com)

In the 1980s, Tanox scientists discovered a novel approach for the treatment of allergic disease by reducing the levels of immunoglobulin E (IgE) in the blood. IgE is one of a class of antibodies that is responsible for causing allergic reactions. In June 2003, an anti-IgE therapy, Xolair® (Omalizumab) For Subcutaneous Use, received approval from the U.S. Food and Drug Administration for the treatment of adults and adolescents (12 years of age and above) with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. In October of 2005, Xolair was approved for marketing in all 25 European Union states and is the first monoclonal antibody approved for the treatment of asthma in Europe. Tanox is committed to becoming a world leader in providing effective therapies for immune-mediated diseases, infectious disease, inflammation and cancer. Through the development and use of innovative technologies, we create products that address unmet medical needs by treating the underlying cause of disease.

## Recent Publications by Tanox:



- [Fungal proteases induce Th2 polarization through limited dendritic cell maturation and reduced production of IL-12.](#)  
*Allergens are capable of polarizing the T cell immune response toward a...*5th June, 2008  
Tanox,- J Immunol. 2008 May 1;180(9):6000-9.
- [Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3.](#)  
*The Notch pathway regulates the development of many tissues and cell types...*13th May, 2008  
Tanox, Incorporated,- J Biol Chem. 2008 Mar 21;283(12):8046-54. Epub 2008 Jan 8. ([DOI Direct Link](#))
- [Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells.](#)

Mammalian cells are used for the production of numerous biologics...18th July, 2007

Cell Culture Sciences, Tanox, Inc., Houston, Texas, USA.- Biotechnol Bioeng. 2007 Jul 1;97(4):877-92.  
([DOI Direct Link](#))

- [Mast cell and immune inhibitory receptors.](#)

*Modulation by balancing activating and inhibitory receptors constitutes an...*1st April, 2006

Tanox, Inc. 10555 Stella link, Houston, Texas 77025, USA.- Cell Mol Immunol. 2004 Dec;1(6):408-15.

- [Identification and expression of a new type II transmembrane protein in human mast cells.](#)

*A cDNA encoding a new type II transmembrane protein has been isolated from...*13th January, 2006

Tanox, Inc., 10301 Stella Link Road, Suite 110, Houston, TX 77025, USA.- Genomics. 2005

Jul;86(1):68-75. Epub 2005 Apr 15. ([DOI Direct Link](#))

- [A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils.](#)

*BACKGROUND: FcγRIIB are low-affinity immunoglobulin (Ig)G receptors...*21st May, 2005

Tanox Inc., Houston, TX, USA.- Allergy. 2004 Jul;59(7):772-80. ([DOI Direct Link](#))

- [Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts.](#)

*BACKGROUND: Amphiregulin is a member of the epidermal growth factor family...*23rd March, 2005

Tanox, Inc., Houston, TX 77025, USA.- J Allergy Clin Immunol. 2005 Feb;115(2):287-94. ([DOI Direct](#)

[Link](#))

- [RACHITT: Gene family shuffling by Random Chimeragenesis on Transient Templates.](#)

*Complement C5a is aetiologically linked to inflammatory tissue damage in...*13th November, 2003

Tanox Inc., Houston, TX, USA.- Methods Mol Biol. 2003;231:111-27. ([DOI Direct Link](#))

- [Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.](#)

*Complement C5a is aetiologically linked to inflammatory tissue damage in...*17th September, 2003

Tanox- Clin Exp Immunol. 2003 Aug;133(2):160-9.

- [Calcineurin/nuclear factors of activated T cells \(NFAT\)-activating and immunoreceptor tyrosine-based activation motif \(ITAM\)-containing protein \(CNAIP\), a novel ITAM-containing protein that activates the calcineurin/NFAT-signaling pathway.](#)

*We report in this study the identification and characterization of a novel...*2nd July, 2003

Department of Exploratory Biology, Tanox, Inc., Houston, Texas 77025, USA.- J Biol Chem. 2003 May

9;278(19):16797-801. Epub 2003 Mar 3. ([DOI Direct Link](#))

- [Growth factor engineering by degenerate homoduplex gene family recombination.](#)

*There is great interest in engineering human growth factors as potential...*7th June, 2003

Enchira Biotechnology Corporation, 4200 Research Forest Drive, The- Nat Biotechnol. 2002

Dec;20(12):1246-50. Epub 2002 Nov 11. ([DOI Direct Link](#))

- [Comparison of four artificial neural network software programs used to predict the in vitro dissolution of controlled-release tablets.](#)

*The purpose of this study was to evaluate four commercially available...*18th April, 2003

Tanox, Inc., 10301 Stella- Pharm Dev Technol. 2002;7(3):373-9. ([DOI Direct Link](#))

## Press Releases on Tanox:

### [New Report from](#)

### [PharmaPlus: HIV Pipelines](#)

### [& Deals](#)

1st December, 2003

Pharmaplus

*New Report from  
PharmaPlus: HIV Pipelines  
& Deals At the end of  
November 2003 the joint  
United Nations Program  
on HIV/AIDS and the  
World Health Organization  
presented*

<a href="#">Food Allergies: Drug makers set to capitalize?</a>	1st July, 2003	Datamonitor	<i>Food Allergies: Drug makers set to capitalize? Although food allergies have been recognized in the medical community since the beginning of the century, they have recently been</i>
<a href="#">Wong's BioTech Stock Report - outlook on allergic asthma ("asthma")</a>	1st May, 2003	Biotechsage	<i>Wong's BioTech Stock Report - outlook on allergic asthma ("asthma") therapeutics</i>
<a href="#">Biotech Tracker News - Xolair BLA Re-Submitted</a>	1st August, 2001	Biotracker	<i>Biotech Tracker News - Xolair BLA Re-Submitted December 19,</i>
<a href="#">Profile of Tanox</a>	1st January, 1970	Biotracker	<i>Biotech Tracker News - Profile of Tanox</i>

#### BioNews Results for Tanox



- [Cytovance Biologics Announces the Hiring of Dr. Jeffrey Su as Vice President of Bioanalytical Development to O](#)  
*Pharma Live: Aug 31 2009 2:56PM Matching: tanox*

#### Tanox Clinical Trials:



- [TNX-355 With Optimized Background Therapy \(OBT\) in Treatment-Experienced Subjects With HIV-1](#)

#### Tanox Patents:



- 5428133- [Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but not IgE bound to FC receptors on basophils](#)
- 5854400- [Monoclonal antibodies which neutralize HIV-1 infection](#)
- 5866129- [Method of producing an antibody with a peptide corresponding to membrane-bound IgA](#)
- 5872222- [Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants](#)
- 5908626- [Hybrid with interferon-.beta. and an immunoglobulin Fc joined by a peptide linker](#)
- 5958708- [Reshaped monoclonal antibodies against an immunoglobulin isotype](#)
- 5981278- [Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS](#)
- 6066718- [Reshaped monoclonal antibodies against an immunoglobulin isotype](#)
- 6072035- [Reshaped monoclonal antibodies against an immunoglobulin isotype](#)
- 6106835- [Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators](#)
- 6117982- [Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators](#)
- 5834599- [Immunoconjugates which neutralize HIV-1 infection](#)
- 5739306- [gC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies](#)
- 5728814- [GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies](#)
- 5449760- [Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils](#)
- 5484907- [Nucleotides coding for the extracellular membrane-bound segment of IgA](#)
- 5514776- [Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface](#)
- 5543144- [Treating hypersensitivities with anti-IGE monoclonal antibodies which bind to IGE-expressing B cells but not basophils](#)
- 5614611- [Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils](#)
- 5652333- [gC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies](#)
- 5670626- [Allergen-specific human IgA monoclonal antibodies for mucosal administration](#)
- 5690934- [Peptides relating to the extracellular membrane-bound segment of human alpha chain](#)
- 5691447- [GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies](#)
- 5723125- [Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide](#)
- 6129916- [Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates](#)
- 6177548- [Enhanced aggregate removal from bulk biologicals using ion exchange chromatography](#)
- 6903195- [Methods and compositions for detecting CDN apoptosis-modulating proteins](#)
- 6956107- [Inhibitors of complement activation](#)
- 6998468- [Anti-C2/C2a inhibitors of complement activation](#)
- 7045596- [Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof](#)
- 7045604- [Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof](#)
- 7108989- [Apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof](#)
- 7112327- [Inhibition of complement activation](#)
- 7118743- [Bispecific molecules cross-linking ITIM and ITAM for therapy](#)
- 7316915- [Bak binding protein, DNA encoding the protein, and methods of use thereof](#)
- 7479552- [Type-1 ribosome-inactivating protein](#)

- 6787524- [CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies](#)
- 6767540- [Use of antagonists of plasminogen activator inhibitor-1 \(PAI-1\) for the treatment of asthma and chronic obstructive pulmonary disease](#)
- 6685930- [Methods and substances for recruiting therapeutic agents to solid tumors](#)
- 6197298- [Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals](#)
- 6309880- [Antibodies specific for CD4-binding domain of HIV-1](#)
- 6433155- [Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof](#)
- 6436639- [Bak promoter expression system](#)
- 6441135- [Bak binding protein, DNA encoding the protein, and methods of use thereof](#)
- 6534058- [Anti-C5 monoclonal antibodies](#)
- 6586395- [Apoptosis-modulating proteins](#)
- 6645494- [Anti-CD40L immunotoxins for the treatment of diseases](#)
- 6657050- [Chimeric viral-neutralizing immunoglobulins](#)
- 6680296- [Type-1 ribosome-inactivating protein](#)
- 7531169- [High affinity anti-human IgE antibodies](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

